UBS AM
AMLX icon

UBS AM’s Amylyx Pharmaceuticals AMLX Stock Holding History

UBS AM’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.11M Buy
173,407
+16,318
+10% +$252K ﹤0.01% 1860
2026
Q1 		$2.18M Buy
157,089
+58,251
+59% +$819K ﹤0.01% 2007
2025
Q4 		$1.19M Buy
+98,838
New +$1.34M ﹤0.01% 2080
2024
Q2 		– Sell
-19,700
Closed -$55.9K – 2801
2024
Q1 		$55.9K Hold
19,700
– – ﹤0.01% 2503
2023
Q4 		$290K Sell
19,700
-8,100
-29% -$124K ﹤0.01% 2423
2023
Q3 		$509K Buy
+27,800
New +$588K ﹤0.01% 2290

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

UBS AM's AMLX Position: Q2 2026 in Review

UBS AM increased its Amylyx Pharmaceuticals (AMLX) stake by 10% in Q2 2026, buying an estimated $252K and bringing the position to 173,407 shares worth $3.11M. The position accounts for ﹤0.01% of the portfolio, ranked #1860.

UBS AM first reported a position in AMLX in Q3 2023 and has held it in 6 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • UBS AM held 173,407 shares of Amylyx Pharmaceuticals worth $3.11M as of Q2 2026.
  • UBS AM bought 16,318 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $252K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1860 holding.
  • UBS AM first reported a position in Amylyx Pharmaceuticals in Q3 2023 and has held it in 6 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.